These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial. Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751 [TBL] [Abstract][Full Text] [Related]
6. In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA Belal H; Gandhi GY Ann Intern Med; 2023 Oct; 176(10):JC113. PubMed ID: 37782932 [TBL] [Abstract][Full Text] [Related]
7. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Philis-Tsimikas A; Asong M; Franek E; Jia T; Rosenstock J; Stachlewska K; Watada H; Kellerer M Lancet Diabetes Endocrinol; 2023 Jun; 11(6):414-425. PubMed ID: 37148899 [TBL] [Abstract][Full Text] [Related]
8. Once-Weekly Insulin Icodec Ribeiro E Silva R; de Miranda Gauza M; Guisso MES; da Silva JON; Kohara SK Arch Endocrinol Metab; 2023 May; 67(5):e000614. PubMed ID: 37249450 [TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes With Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Insulin-Naïve and Previously Insulin-Treated Individuals With Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials. Ahmed M; Shafiq A; Javaid H; Jain H; Nashwan AJ; Tul-Ain Q; Basit J Endocrinol Diabetes Metab; 2024 May; 7(3):e00480. PubMed ID: 38659132 [TBL] [Abstract][Full Text] [Related]
11. Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4. Bajaj HS; Ásbjörnsdóttir B; Carstensen L; Laugesen C; Mathieu C; Philis-Tsimikas A; Battelino T Diabetes Care; 2024 Apr; 47(4):729-738. PubMed ID: 38380954 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials. Shetty S; Suvarna R Diabetes Obes Metab; 2024 Mar; 26(3):1069-1081. PubMed ID: 38192022 [TBL] [Abstract][Full Text] [Related]
13. In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA Griffin TP; Dinneen SF Ann Intern Med; 2021 Mar; 174(3):JC34. PubMed ID: 33646841 [TBL] [Abstract][Full Text] [Related]
14. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial. Bajaj HS; Aberle J; Davies M; Donatsky AM; Frederiksen M; Yavuz DG; Gowda A; Lingvay I; Bode B Ann Intern Med; 2023 Nov; 176(11):1476-1485. PubMed ID: 37748181 [TBL] [Abstract][Full Text] [Related]
15. In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA Liakos A; Karagiannis T; Tsapas A Ann Intern Med; 2024 Jan; 177(1):JC6. PubMed ID: 38163368 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes. Hövelmann U; Engberg S; Heise T; Kristensen NR; Nørgreen L; Zijlstra E; Ribel-Madsen R Diabetes Obes Metab; 2024 May; 26(5):1941-1949. PubMed ID: 38379002 [TBL] [Abstract][Full Text] [Related]
17. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Russell-Jones D; Babazono T; Cailleteau R; Engberg S; Irace C; Kjaersgaard MIS; Mathieu C; Rosenstock J; Woo V; Klonoff DC Lancet; 2023 Nov; 402(10413):1636-1647. PubMed ID: 37863084 [TBL] [Abstract][Full Text] [Related]